Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Ixazomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 17 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 10 Jan 2019.
- 23 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
- 28 Aug 2018 New trial record